阿立哌唑与利培酮治疗精神分裂症的疗效与安全性对比分析

Analysis of Efficacy and Safety of Aripiprazole and Risperidone in the Treatment of Schizophrenia

目的:探讨阿立哌唑与利培酮治疗精神分裂症的收益和风险,优化临床治疗效果与安全性,指导临床合理治疗。方法:将60例符合入组标准的精神分裂症按随机数字表分为阿立哌唑组与利培酮组,各30例,分别给予阿立哌唑与利培酮,8周为1个疗程,治疗前、后观察患者症状,进行阳性症状量表和阴性症状量表(PANSS)评分及不良反应量表(TESS)评分,评价两组患者的临床疗效与安全性。结果:阿立哌唑组和利培酮组的总有效率均为93.33%,P>0.05;阿立哌唑组和利培酮组的阳性症状量表(PANSS)评分、阴性症状量表(PANSS)评分及量表总评分差异均无统计学意义,均P>0.05;阿立哌唑组和利培酮组头痛、口干、血压降低、失眠差异无统计学意义,均P>0.05,但阿立哌唑组锥体外系反应、体质量增加、闭经溢乳的发生率明显低于利培酮,差异具有统计学意义,均P<0.05。结论:阿立哌唑起效速度、安全性、依从性明显优于利培酮,尤其能明显降低现锥体外系反应、体质量增加、闭经溢乳的副反应,是治疗精神分裂症的首选药物。

Objective： To investigate benefits and risks of aripiprazole and risperidone in the treatment of schizophrenia, to optimize clinical efficacy and safety, guide clinical treatment. Methods： 60 schizophrenia patients met the inclusion criteria were randomly divided into aripiprazole group and risperidone group, 30 cases of each group, each group were given aripiprazole and risperidone, 8 weeks for an effect, observed symptoms, made a positive and negative symptom scale symptom scale （PANSS） scores and adverse reactions scale （TESS） scores, to evaluate the clinical efficacy and safety. Results：The total effective rate of aripiprazole group and risperidone group was 93. 33%, P〉0. 05;the positive symptom scale （PANSS） score, negative syndrome scale （PANSS） score, scale total score of aripiprazole group and risperidone group were not statistically significant, all P〉0. 05;headache, dry mouth, decreased blood pressure, insomnia of aripiprazole group was not statistically significant than and the risperidone group, all P〉0. 05, but the extrapyramidal reactions, body mass increases, the incidence of amenorrhea galactorrhea of aripiprazole group was significantly lower than the risperidone group, all P〈0. 05. Conclusion： The onset speed, security, compliance of aripiprazole were significantly better than risperidone, in particular, can significantly reduce the existing extrapyramidal reactions, weight gain, amenorrhea galactorrhea side effects, is preferred drug in the treatment of schizophrenia.